MX2015015393A - Derivado de acido cicloalquilo, metodo de preparacion del mismo, y aplicacion farmaceutica del mismo. - Google Patents
Derivado de acido cicloalquilo, metodo de preparacion del mismo, y aplicacion farmaceutica del mismo.Info
- Publication number
- MX2015015393A MX2015015393A MX2015015393A MX2015015393A MX2015015393A MX 2015015393 A MX2015015393 A MX 2015015393A MX 2015015393 A MX2015015393 A MX 2015015393A MX 2015015393 A MX2015015393 A MX 2015015393A MX 2015015393 A MX2015015393 A MX 2015015393A
- Authority
- MX
- Mexico
- Prior art keywords
- acid derivative
- preparation
- cycloalkyl
- cycloalkyl acid
- pharmaceutical application
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940083914 URAT1 inhibitor Drugs 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de ácido cicloalquilo, un método de preparación del mismo, y un aplicación farmacéutica del mismo, y en particular, la presente invención se refiere a un derivado de ácido cicloalquilo representado por la fórmula general (I) y una sal médica del mismo, un método de preparación del mismo, y una aplicación del derivado de ácido cicloalquilo y la sal médica del mismo como inhibidores URAT1, y particularmente como agentes terapéuticos para enfermedades relacionadas con un nivel de ácido anormal, en donde las definiciones de los grupos sustituyentes en la fórmula general (I) son los mismos como las definiciones en las especificaciones. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310174990 | 2013-05-13 | ||
| PCT/CN2014/076447 WO2014183555A1 (zh) | 2013-05-13 | 2014-04-29 | 环烷基甲酸类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015393A true MX2015015393A (es) | 2016-03-15 |
| MX362747B MX362747B (es) | 2019-02-05 |
Family
ID=51897690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015393A MX362747B (es) | 2013-05-13 | 2014-04-29 | Derivado de ácido cicloalquilo, método de preparación del mismo, y aplicación farmacéutica del mismo. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9637484B2 (es) |
| EP (1) | EP2998296B1 (es) |
| JP (1) | JP6440690B2 (es) |
| KR (1) | KR102240158B1 (es) |
| CN (1) | CN104470898B (es) |
| AU (1) | AU2014267974B2 (es) |
| BR (1) | BR112015027303B1 (es) |
| CA (1) | CA2923269C (es) |
| CY (1) | CY1120515T1 (es) |
| DK (1) | DK2998296T3 (es) |
| ES (1) | ES2668721T3 (es) |
| HU (1) | HUE037512T2 (es) |
| LT (1) | LT2998296T (es) |
| MX (1) | MX362747B (es) |
| NO (1) | NO2998296T3 (es) |
| PL (1) | PL2998296T3 (es) |
| PT (1) | PT2998296T (es) |
| TR (1) | TR201807104T4 (es) |
| TW (1) | TWI654172B (es) |
| WO (1) | WO2014183555A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10196361B2 (en) * | 2015-05-27 | 2019-02-05 | Jiangsu Hengrui Medicine Co., Ltd. | Sodium salt of uric acid transporter inhibitor and crystalline form thereof |
| BR112018006873A2 (pt) | 2015-10-05 | 2018-11-06 | The Trustees Of Columbia University In The City Of New York | ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias |
| AU2016368240B2 (en) * | 2015-12-07 | 2020-01-02 | Hinova Pharmaceuticals Inc. | Quinoline compounds, preparation method thereof, and use thereof as urate transporter inhibitor drug |
| CN107286156A (zh) * | 2016-04-05 | 2017-10-24 | 江苏新元素医药科技有限公司 | 新型urat1抑制剂及其在医药上的应用 |
| WO2018090921A1 (zh) | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
| CN108201529B (zh) * | 2016-12-16 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种含有尿酸转运蛋白抑制剂的药物组合物及其制备方法 |
| US10995087B2 (en) | 2017-11-23 | 2021-05-04 | Medshine Discovery Inc. | Crystal form of URAT1 inhibitor, and preparation method therefor |
| CN110452168B (zh) * | 2018-05-07 | 2022-03-15 | 中国医学科学院药物研究所 | N-苯基-n-喹啉羧酸类化合物及其制法和药物用途 |
| CN110467571B (zh) * | 2018-05-11 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 一种制备环烷基甲酸类衍生物或其可药用盐的方法 |
| WO2020088641A1 (zh) * | 2018-11-02 | 2020-05-07 | 江苏恒瑞医药股份有限公司 | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 |
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN114315705B (zh) * | 2020-09-29 | 2024-02-20 | 杭州中美华东制药有限公司 | 一类urat1抑制剂及其制备方法与用途 |
| CN118439998A (zh) * | 2021-05-19 | 2024-08-06 | 江苏正大清江制药有限公司 | 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用 |
| AU2023285760B2 (en) * | 2021-05-19 | 2025-07-10 | Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd. | Quinoline Mercaptoacetate Sulfonamide Derivative, Intermediate, Pharmaceutical Derivative Or Formulation, And Preparation Method And Use Therefor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| AR053602A1 (es) | 2005-05-03 | 2007-05-09 | Smithkline Beecham Corp | Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento |
| JP5516397B2 (ja) | 2007-04-05 | 2014-06-11 | アムジエン・インコーポレーテツド | オーロラキナーゼ調節物質及び使用方法 |
| TW200916098A (en) | 2007-06-14 | 2009-04-16 | Teijin Pharma Ltd | Agent for lowering uric acid level |
| EP2217577B1 (en) | 2007-11-27 | 2014-08-06 | Ardea Biosciences, Inc. | Novel compounds and compositions and methods of use |
| JPWO2010044403A1 (ja) | 2008-10-15 | 2012-03-15 | キッセイ薬品工業株式会社 | ５員環ヘテロアリール誘導体及びその医薬用途 |
| WO2011046800A1 (en) | 2009-10-13 | 2011-04-21 | Wellstat Therapeutics Corporation | 3-substituted compounds for reducing uric acid |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| TWI499412B (zh) * | 2010-06-16 | 2015-09-11 | Ardea Biosciences Inc | 苯基硫乙酸酯組合物及其使用方法 |
-
2014
- 2014-04-29 WO PCT/CN2014/076447 patent/WO2014183555A1/zh active Application Filing
- 2014-04-29 BR BR112015027303-3A patent/BR112015027303B1/pt active IP Right Grant
- 2014-04-29 AU AU2014267974A patent/AU2014267974B2/en active Active
- 2014-04-29 HU HUE14798044A patent/HUE037512T2/hu unknown
- 2014-04-29 NO NO14798044A patent/NO2998296T3/no unknown
- 2014-04-29 KR KR1020157034797A patent/KR102240158B1/ko active Active
- 2014-04-29 ES ES14798044.5T patent/ES2668721T3/es active Active
- 2014-04-29 PT PT147980445T patent/PT2998296T/pt unknown
- 2014-04-29 TR TR2018/07104T patent/TR201807104T4/tr unknown
- 2014-04-29 CA CA2923269A patent/CA2923269C/en active Active
- 2014-04-29 EP EP14798044.5A patent/EP2998296B1/en active Active
- 2014-04-29 CN CN201480001853.5A patent/CN104470898B/zh active Active
- 2014-04-29 PL PL14798044T patent/PL2998296T3/pl unknown
- 2014-04-29 US US14/889,563 patent/US9637484B2/en active Active
- 2014-04-29 MX MX2015015393A patent/MX362747B/es active IP Right Grant
- 2014-04-29 JP JP2016513214A patent/JP6440690B2/ja active Active
- 2014-04-29 LT LTEP14798044.5T patent/LT2998296T/lt unknown
- 2014-04-29 DK DK14798044.5T patent/DK2998296T3/en active
- 2014-05-09 TW TW103116499A patent/TWI654172B/zh active
-
2018
- 2018-06-13 CY CY20181100621T patent/CY1120515T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1205118A1 (zh) | 2015-12-11 |
| BR112015027303B1 (pt) | 2023-04-25 |
| MX362747B (es) | 2019-02-05 |
| US20160108035A1 (en) | 2016-04-21 |
| JP6440690B2 (ja) | 2018-12-19 |
| CA2923269C (en) | 2023-02-14 |
| AU2014267974A1 (en) | 2015-11-12 |
| TR201807104T4 (tr) | 2018-06-21 |
| KR102240158B1 (ko) | 2021-04-15 |
| PL2998296T3 (pl) | 2018-12-31 |
| CY1120515T1 (el) | 2019-07-10 |
| KR20160006207A (ko) | 2016-01-18 |
| AU2014267974B2 (en) | 2018-08-30 |
| CN104470898B (zh) | 2016-04-06 |
| JP2016520072A (ja) | 2016-07-11 |
| WO2014183555A1 (zh) | 2014-11-20 |
| CN104470898A (zh) | 2015-03-25 |
| US9637484B2 (en) | 2017-05-02 |
| EP2998296B1 (en) | 2018-03-14 |
| LT2998296T (lt) | 2018-08-10 |
| HUE037512T2 (hu) | 2018-08-28 |
| CA2923269A1 (en) | 2014-11-20 |
| BR112015027303A2 (es) | 2017-09-05 |
| ES2668721T3 (es) | 2018-05-21 |
| EP2998296A1 (en) | 2016-03-23 |
| PT2998296T (pt) | 2018-06-15 |
| TW201443010A (zh) | 2014-11-16 |
| NO2998296T3 (es) | 2018-08-11 |
| DK2998296T3 (en) | 2018-05-22 |
| TWI654172B (zh) | 2019-03-21 |
| EP2998296A4 (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015015393A (es) | Derivado de acido cicloalquilo, metodo de preparacion del mismo, y aplicacion farmaceutica del mismo. | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
| WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| MX376054B (es) | Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo. | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| MX2015010971A (es) | Derivado novedoso de pirazol. | |
| MX356341B (es) | Agente de control de endoparasitos. | |
| HK1226393A1 (zh) | 用於治療疾病的葡萄糖神經醯胺合成酶抑制劑 | |
| MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
| MX361653B (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
| BR112013020996A2 (pt) | derivados aminobutíricos substituídos como inibidores de neprilisina | |
| IN2015MN00404A (es) | ||
| GEP201706623B (en) | Pyrrolotriazinone derivatives as pi3k inhibitors | |
| IN2015DN01151A (es) | ||
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| PH12016501461A1 (en) | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors | |
| PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
| NZ719028A (en) | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| MX2014013758A (es) | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. | |
| AU2015280874A1 (en) | Novel heterocyclic compound | |
| NZ720805A (en) | Processes for the preparation of pyrimidinylcyclopentane compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |